236 related articles for article (PubMed ID: 23944387)
1. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Chaumais MC; Perrin S; Sitbon O; Simonneau G; Humbert M; Montani D
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1193-205. PubMed ID: 23944387
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
3. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
Wung D
Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
5. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
Tay EL; Geok-Mui MK; Poh-Hoon MC; Yip J
Int J Cardiol; 2008 Apr; 125(3):416-7. PubMed ID: 17407795
[No Abstract] [Full Text] [Related]
6. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
7. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Sakuma M; Shirato K
Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
[TBL] [Abstract][Full Text] [Related]
8. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
Levin YD; White RJ
Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Sabri MR; Beheshtian E
Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
[TBL] [Abstract][Full Text] [Related]
11. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Channick R; Preston I; Klinger JR
Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
[TBL] [Abstract][Full Text] [Related]
12. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
Takatsuki S; Calderbank M; Ivy DD
Pediatr Cardiol; 2012 Jun; 33(5):683-8. PubMed ID: 22402804
[TBL] [Abstract][Full Text] [Related]
14. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil for the treatment of pulmonary hypertension in children.
Beghetti M; Wacker Bou Puigdefabregas J; Merali S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1157-84. PubMed ID: 25223406
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil for the treatment of pulmonary arterial hypertension.
Rosenzweig EB
Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?
Nyp M; Sandritter T; Poppinga N; Simon C; Truog WE
J Perinatol; 2012 Jan; 32(1):64-9. PubMed ID: 21941230
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
